Esther Vazquez's Contact Details

Esther Vazquez's Company Details

Nanoligent

Cerdanyola, Catalunya, Spain • 9 Employees
Research

Our mision is to improve the life of patients by designing new medicines that selectively target the cells affected by disease. With this approach we develope treatments that are more effective and have fewer adverse effects than classical drugs.We design our new drugs using state-of-the-art protein engineering and nanobiotechnology.First Project: New anti-metastatic drugSince cancer is the second cause of death worlwide, there is an urgent need for more effective and personalized treatments of tumors.Metastasis development is the main cause of patient death in most tumor types but the control of metastasis in cancer is still an unmet medical need. The current surgery-based approaches and conventional chemotherapy can be enhanced using new technologies.Our first project is a self-assembling protein nanoparticle that selectively kills metastatic cells. This nanoconjugate targets CXCR4 receptors which are over-expressed in metastatic cells of many types of cáncer.Preclinical results look very promising: in vivo results show that our drug-loaded nanoconjugate accumulates in primary tumor and metastatic foci with negible presence in liver, kidney, brain or other organs. The result is a significant decrease of the number of metastatic foci and very low toxicity on normal cells.Our focus now is to complete preclinical development in order to obtain approval for first-in-human trial.